PriceTargets.com logo

Elevation Oncology - ELEV Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.80
  • Forecasted Upside: 1,367.54%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$0.53 As of 11/15/2024 01:00 AM ET
▼ -0.05 (-8.60%)

This chart shows the closing price for ELEV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Elevation Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELEV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELEV

Analyst Price Target is $7.80
▲ +1,367.54% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Elevation Oncology in the last 3 months. The average price target is $7.80, with a high forecast of $10.00 and a low forecast of $6.00. The average price target represents a 1,367.54% upside from the last price of $0.53.

This chart shows the closing price for ELEV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Elevation Oncology. This rating has held steady since October 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
8/6/2024WedbushReiterated RatingOutperform$8.00
7/15/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$7.00 ➝ $7.00
6/28/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$7.00 ➝ $7.00
5/31/2024Piper SandlerInitiated CoverageOverweight$10.00
5/14/2024StephensInitiated CoverageOverweight$8.00
5/3/2024WedbushReiterated RatingOutperform ➝ Outperform$8.00
4/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00
3/7/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$7.00
3/7/2024WedbushBoost TargetOutperform ➝ Outperform$5.00 ➝ $8.00
3/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00
3/1/2024JMP SecuritiesInitiated CoverageOutperform$7.00
2/20/2024HC WainwrightBoost TargetBuy ➝ Buy$1.50 ➝ $6.00
11/6/2023WedbushReiterated RatingOutperform ➝ Outperform$5.00
9/29/2023HC WainwrightInitiated CoverageBuy$1.50
5/30/2023Leerink PartnersUpgradeMarket Perform ➝ Outperform
5/30/2023SVB SecuritiesUpgradeMarket Perform ➝ Outperform$5.00 ➝ $8.00
3/10/2023WedbushReiterated RatingOutperform$4.00
11/10/2022JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
11/7/2022Leerink PartnersDowngradeOutperform ➝ Market Perform$11.00 ➝ $2.00
9/19/2022HC WainwrightReiterated RatingBuy$7.50
8/8/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
7/29/2022WedbushLower TargetOutperform$15.00 ➝ $8.00
7/27/2022Leerink PartnersReiterated RatingOutperform
5/6/2022WedbushLower TargetOutperform$21.00 ➝ $15.00
3/4/2022WedbushLower TargetOutperform$27.00 ➝ $21.00
12/23/2021HC WainwrightInitiated CoverageBuy$12.00
7/20/2021JPMorgan Chase & Co.Initiated CoverageOverweight$24.00
7/20/2021WedbushInitiated CoverageOutperform$27.00
7/20/2021Leerink PartnersInitiated CoverageOutperform$20.00
7/20/2021CowenInitiated CoverageOutperform$12.10
(Data available from 11/17/2019 forward)

News Sentiment Rating

-0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
4/21/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Elevation Oncology logo
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: $0.53
Low: $0.53
High: $0.60

50 Day Range

MA: $0.58
Low: $0.50
High: $0.69

52 Week Range

Now: $0.53
Low: $0.42
High: $5.83

Volume

777,736 shs

Average Volume

839,731 shs

Market Capitalization

$31.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Elevation Oncology?

The following sell-side analysts have issued reports on Elevation Oncology in the last twelve months: HC Wainwright, JMP Securities, Piper Sandler, Stephens, and Wedbush.
View the latest analyst ratings for ELEV.

What is the current price target for Elevation Oncology?

0 Wall Street analysts have set twelve-month price targets for Elevation Oncology in the last year. Their average twelve-month price target is $7.80, suggesting a possible upside of 1,367.5%. Piper Sandler has the highest price target set, predicting ELEV will reach $10.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $6.00 for Elevation Oncology in the next year.
View the latest price targets for ELEV.

What is the current consensus analyst rating for Elevation Oncology?

Elevation Oncology currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ELEV will outperform the market and that investors should add to their positions of Elevation Oncology.
View the latest ratings for ELEV.

What other companies compete with Elevation Oncology?

Other companies that are similar to Elevation Oncology include Bolt Biotherapeutics, Rain Oncology, SCYNEXIS, Candel Therapeutics and Alto Neuroscience. Learn More about companies similar to Elevation Oncology.

How do I contact Elevation Oncology's investor relations team?

The company's listed phone number is 716-371-1125 and its investor relations email address is [email protected]. The official website for Elevation Oncology is www.elevationoncology.com. Learn More about contacing Elevation Oncology investor relations.